Innate Pharma (IPHA) Return on Assets (2020 - 2025)

Innate Pharma (IPHA) has reported Return on Assets for 6 consecutive years, with 0.01% the latest figure, recorded in Q4 2025.

• Quarterly Return on Assets fell 1.0% year-over-year to 0.01% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.01% (down 1.0% YoY) and the FY2022 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Assets slipped to 0.01% in Q4 2025 per IPHA's latest filing, from 0.01% in the prior quarter.
• Over the last five years, Return on Assets for IPHA reached as high as 0.0% in Q2 2023 and fell as low as 0.01% in Q4 2025.
• A 5-year average of 0.0% and a median of 0.0% in 2021 frame the typical range for Return on Assets.
• Annual changes were most pronounced in 2021 — Return on Assets changed 0 bps — and 2024, when it dropped 1 bps.
• Year by year, Return on Assets stood at 0.0% in 2021, then surged by 67 bps to 0.0% in 2022, then surged by 59 bps to 0.0% in 2023, then plunged by 1087 bps to 0.01% in 2024, then tumbled by 92 bps to 0.01% in 2025.
• According to Business Quant data, Return on Assets over the past three periods registered 0.01%, 0.01%, and 0.01% for Q4 2025, Q2 2025, and Q4 2024 respectively.